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Dietary compounds in fruits and vegetables have been shown to exert many biological activities. In addition
to antioxidant eﬀects, a number of ﬂavonoids are able to modulate inﬂammatory responses. Here, we
demonstrated that phloretin (PT), a natural dihydrochalcone found in many fruits, suppressed the
activation and function of mouse dendritic cells (DCs). Phloretin disturbed the multiple intracellular
signaling pathways in DCs induced by the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS),
including ROS, MAPKs (ERK, JNK, p38 MAPK), and NF-kB, and thereby reducing the production of
inﬂammatory cytokines and chemokines. Phloretin also eﬀectively suppressed the activation of DCs
treated with diﬀerent dosages of LPS or various TLR agonists. The LPS-induced DC maturation was
attenuated by phloretin because the expression levels of the MHC class II and the co-stimulatory
molecules were down-regulated, which then inhibited the LPS-stimulating DCs and the subsequent
na¨ıve T cell activation in a mixed lymphocyte reaction. Moreover, in vivo administration of phloretin
suppressed the phenotypic maturation of the LPS-challenged splenic DCs and decreased the IFN-g
production from the activated CD4 T cells. Thus, we suggest that phloretin may potentially be an
immunomodulator by impairing the activation and function of DCs and phloretin-contained fruits may
be helpful in the improvement of inﬂammation and autoimmune diseases.Introduction
Many components found in dietary plants have benets for
human health. In particular, the antioxidant eﬀect of many
compounds, derived from plant metabolites, is attractive.1,2 In
addition, researchers also focus on the regulatory eﬀect of
inammation by natural compounds and their application in
improving diseases,3 such as asthma, rheumatoid arthritis, and
cardiovascular diseases.4–7 More and more dietary compounds
with health benets are continuously being identied.
Phloretin, a naturally occurring phytochemical found in the
Rosaceae family, is a dihydrochalcone of bicyclic avonoids.8 It
widely exists in the bark, leaves, and fruit of apple trees.4ung Hsing University, Taichung, Taiwan,
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hemistry 2014Phloretin has many biological activities, such as antioxidation,
the regulation of glucose transporters, and anticancer.8–13 With
regards to the study of its anti-inammatory eﬀect, phloretin
signicantly inhibits proinammatory gene expressions, such
as TNF-a, CXCL-10, IL-8 and represses NF-kB-, IP-10-, and IL-8-
promoter driven reporter gene expressions found in the LPS-
stimulated, human acute, monocytic leukemia-derived cell
line.14 Recently, Chang et al. showed that the levels of proin-
ammatory cytokines and mediators, such as NO, PGE2, IL-6,
TNF-a, iNOS and COX-2, are reduced by phloretin via the
suppression of NF-kB and MAPK activation in LPS-stimulated
murine RAW264.7 macrophages.15 However, the eﬀect of
phloretin on the regulation of immune responses is unknown.
Dendritic cells (DCs) are professional antigen-presenting
cells which link innate and adaptive immunity.16 DCs mature as
they meet various stimuli in peripheral tissues, such as pro-
inammatory cytokines and microbial products. Specialized
pattern recognition receptors (PRRs), like the Toll-like receptor
(TLR) family, sense the microbes, and then the DCs translate
the microbial signals to adaptive immunity by presenting
antigens to the T cells.17 Mature DCs reduce antigen-loading,
produce cytokines and chemokines, and enhance the expres-
sion of major histocompatibility complexes (MHC) and acces-
sory molecules, such as CD86, CD80 and CD40.18 In addition to
their role in controlling infections, DCs are also involved in
the pathogenesis of immune disorders, such as chronicFood Funct., 2014, 5, 997–1006 | 997
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View Article Onlineinammation and autoimmunity.19,20 Thus, the modulation of
DC activation and functionmay be a potential way of preventing
or curing these kinds of disease.
In the present study, we evaluate the immunomodulatory
eﬀect of phloretin on DCs. We found that the LPS-induced
activation and the functions of DCs, such as the production of
proinammatory cytokines and chemokines, the expression
level of MHC II and co-stimulatory molecules, and the induc-
tion of T cell activation, were impaired by phloretin. It is sug-
gested that phloretin may possess the ability to modulate
immune responses.Materials and methods
Mice and generation of DCs
C57BL/6 mice were obtained from the National Laboratory
Animal Center (Taipei, Taiwan). All of the mice were housed in
the barrier facility at Taichung Veterans General Hospital (Tai-
chung, Taiwan) and all of the procedures were performed in
accordance with the Institutional Animal Care and Use
Committee guidelines for animal experimentation. DCs were
generated from mouse bone marrow, as described previously.21
Bone marrow (BM) cells were ushed from the femurs and
tibias of the C57BL/6 mice and cultured in a RPMI-1640
medium supplemented with 10% heat-inactivated fetal bovine
serum, 100 U mL1 penicillin G, 100 mg mL1 streptomycin,
2 mM L-glutamine, 20 ng mL1 recombinant mouse IL-4, and
10 ng mL1 recombinant mouse granulocyte–monocyte colony-
stimulating factor (GM-CSF, Peprotech). A fresh medium was
supplied every 2 days, and nonadherent cells were harvested on
day 7. CD11c+ cells were enriched from nonadherent BM cells
by positive selection using an anti-CD11 kit (Miltenyi Biotec)
according to the manufacturer's instructions. The purity of the
CD11c+ cells was >90% which were used for the subsequent
experiments.Phloretin cytotoxicity assay
As previously described,22 the DCs were treated with phloretin
(Sigma-Aldrich, dissolved in DMSO) at the concentrations of
3.125, 6.25, 12.5, 25, 50 and 100 mM for 24 h. Less than 0.1%
(v/v) of DMSO was used in all of the experiments. The viability of
the cultured cells was assessed using the colorimetric assay kit
Cell Counting Kit-8 (CCK-8) according to the manufacturer's
instructions (Sigma-Aldrich).Measurement of cytokine and chemokine production
Supernatants were collected from the DCs (1  106 per mL)
treated with the conditions reported previously.23 The DCs were
pretreated with 0.1% DMSO or the indicated dose of phloretin
for 1 h before TLR stimulation. The TLR ligands, including the
LPS (100 ng mL1, TLR4), Poly I:C (250 mg mL1, TLR3), PGN
(1 mg mL1, TLR2), CpG (200 nM. TLR9), and Imiquimod
(3 mg mL1, TLR7) (which were all from Invivogen) were used to
stimulate the DCs. Aer 18 h (4 h for TNF-alpha and RANTES),
the cytokines (TNF-a, IL-6, IL-12, and IL-10) and chemokines998 | Food Funct., 2014, 5, 997–1006(MIP-1b, and RANTES) were produced in a culture supernatant
and were measured using ELISA (Peprotech).Western blotting
The DCs were pretreated with 0.1% DMSO or phloretin (25 and
50 mM) for 1 h and were immediately stimulated with the LPS
(100 ng mL1). Aer 30 min, the cells were harvested and lysed,
and then SDS-PAGE and western blotting were performed. The
primary antibodies against phospho-p38, protein p38, phospho-
p42/44, protein p42/44, phospho-JNK, NF-kB p65, histone,
b-actin (all from Cell Signaling Technology), and protein JNK
(Santa Cruz Biotechnology) were used and subsequently detec-
ted by HRP-conjugated secondary antibodies (Jackson Immu-
noResearch). The protein signals were then developed with
enhanced chemiluminescence (GE Healthcare) and analyzed
using the LAS3000 system (Fujilm). Densitometric analysis
was performed with Image J soware (National Institute of
Health, MD, USA). Phosphorylated Erk, p38, and JNK were
normalized with their total protein.Assay of NF-kB activation
The DCs were pretreated with 0.1% DMSO or phloretin (25 and
50 mM) for 1 h and were immediately stimulated with the LPS
(100 ng mL1). Aer 30 min, the nuclear extracts of the DCs
were prepared using the NE-PER Nuclear and Cytoplasmic
Extraction system (Pierce) according to the manufacturer's
instructions. The protein concentrations were determined
using a BCA protein assay kit (Pierce). The activated NF-kB in
the nuclear extracts (5 mg mL1 for each assay) was measured
using a TransAM NF-kB p65 ELISA kit (Active Motif) according
to the manufacturer's instructions.Measurement of Reactive Oxygen Species (ROS)
To detect the intracellular ROS level, the DCs (3  105 cells
mL1) were cultured in the presence of 0.1% DMSO (control) or
phloretin (25 and 50 mM) for 1 h and then stimulated with the
LPS (100 ng mL1) for 3 h. Aer stimulation, the media were
replaced by a fresh medium containing 10 mM 5-(and 6)-car-
boxy-20,70-dichlorodihydrouorescein diacetate (DCFDA,
Molecular Probes) and the cultures were kept in the dark for 30
min at 37 C before being thoroughly washed with PBS. The
uorescent signal was detected and analyzed by ow cytometry.Assay for the eﬀect of specic inhibitors
To conrm the molecular mechanism of phloretin reducing the
TLR4 signaling pathway, the DCs were pretreated with various
specic inhibitors, including SB203580 (for p38 MAPK, 10 mM),
JNKI (for JNK, 10 mM), PD98059 (for ERK, 10 mM), BAY 11-7082
(for NF-kB, 10 mM) (all from Calbiochem), N-acetyl-L-cysteine
(NAC for ROS, 10 mM), or cobalt protoporphyrin-IX (CoPP-IX for
ROS, 50 mM) (all from Sigma-Aldrich) for 1 h and then incubated
with the LPS for 30 min. The production of cytokine from the
LPS-stimulated DCs was determined by ELISA, as described
previously.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineAnalysis of the DC maturation
The DC maturation was determined by the upregulation of the
MHC class II and costimulatory molecule expression, as
described previously.24 The cells were pretreated with 0.1%
DMSO or phloretin (25 and 50 mM) for 1 h and stimulated with
the LPS for 18 h, and then stained with mAbs which are specic
for mouse CD11c, I-Ab, CD40 and CD80 (Biolegend) as well as
with isotype-matched control antibodies. The expression levelsFig. 1 Phloretin eﬃciently inhibited DC activation. (A) The cytotoxicity of
DCs were analyzed by a CCK-8 assay kit. (B) The production of cytokine
collected from the phloretin-treated LPS-stimulated DCs after 18 h (4 h fo
stimulated DCs at diﬀerent time points. The DCs were treated with p
supernatants were harvested to determine the TNF-a production. (D) T
diﬀerent doses of the LPS. (E) The inhibitory eﬀect of phloretin (50 mM) on
the mean  SD of triplicate repeats. *p < 0.05, **p < 0.01, ***p < 0.001;
This journal is © The Royal Society of Chemistry 2014of eachmolecule were analyzed by ow cytometry and the results
were analyzed by WINMDI soware (Scripps, La Jolla, CA, USA).
Allogenic mixed lymphocyte reaction
The DC-induced T cell activation was assayed by an allogenic
mixed lymphocyte reaction, as described previously.25 The T
cells were isolated from the spleen of Balb/c mice using an Easy-
Sep Mouse T Cell Enrichment Kit according to thephloretin (PT) on immature (without the LPS) and mature (with the LPS)
s and chemokines were determined by ELISA. The supernatants were
r TNF-a and RANTES). (C) The inhibitory eﬀect of phloretin on the LPS-
hloretin (50 mM) for 1 h before or after the LPS stimulation and the
he inhibitory eﬀect of phloretin (50 mM) on the DCs stimulated with
the DCs stimulated with various TLR ligands. The data are expressed as
similar results were obtained from the three independent experiments.
Food Funct., 2014, 5, 997–1006 | 999
Fig. 2 Phloretin disturbed MAPK activation and NF-kB translocation in
the LPS-stimulated DCs. The DCs were pretreated with DMSO or
phloretin (25 and 50 mM) for 1 h and then stimulated with 100 ng mL1
LPS for 30 min, and lysed immediately for assaying protein phos-
phorylation. (A) The phosphorylation of ERK, JNK, and p38 MAPK in the
DCs was determined by western blotting. The total ERK, JNK, and p38
MAPK proteins were used for loading control, respectively. The results
1000 | Food Funct., 2014, 5, 997–1006
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View Article Onlinemanufacturer's instructions (Stem Cell Technologies). Imma-
ture DCs were pretreated with 0.1% DMSO or phloretin (25 and
50 mM) for 1 h and stimulated with the LPS (100 ng mL1) for 18
h, and then the cells were incubated with enriched T cells at
ratios of 1 : 2, 1 : 5, and 1 : 10 (DC : T) in 96-well round-bottom
plates (Corning). Aer 96 h, the cells were pulsed with 1 mCi of
[3H] thymidine (GE Healthcare) overnight, and the incorporated
[3H] thymidine was subsequently determined by liquid scintil-
lation counting using a b-Counter (Beckman Instruments).
Assay of the DC and T cells activation in vivo
The mice were injected intraperitoneally (i.p.) with phloretin
(10 mg kg1) every 2 days for three times. Aer the last injection,
mice were injected i.p. with 4 mg kg1 LPS (E. coli 0111.B4;
Sigma) for 12 h. Then, the mice were sacriced and the spleno-
cytes were seeded in 6-well plates in the complete RPMI 1640
medium (L-glutamine, 10% fetal calf serum, 1% sodium pyruvate,
1% penicillin/streptomycin, 1% non-essential amino acids and
0.01% 2-mercaptoethanol) overnight. The CD11c+ cells were then
enriched using anti-CD11c microbeads and the expression of
maturationmarkers (I-Ab, CD40 and CD80) was examined by ow
cytometry. In order to analyze the CD4+ T cell activation, the
interferon-gamma (IFN-g) production by the CD4 T cells was
determined. The splenocytes (3  105 cells per well) were plated
in a round-bottom 96-well plate in the complete RPMI 1640
medium (200 mL), containing phorbol 12-myristate 13-acetate
(PMA, 5 ng mL1) and ionomycin (1 mg mL1) for 6 h. Brefeldin A
(5 mg mL1, Sigma-Aldrich) was added during the last 4 h of
incubation before the cells were harvested for surface staining
with the phycoerythrin (PE)-conjugated anti-CD4 antibody
(eBioscience). Then, the cells were intracellularly stained with the
FITC-conjugated anti-IFN-gamma antibody (eBioscience) using a
Cytox/Cytoperm Plus kit (BD Biosciences). The percentage of
CD4+ IFN-g+ cells was determined by ow cytometry.
Data analysis
All data were analyzed using the GraphPad Prism soware
package version 4.0. The statistical analyses of the cytokine
production, the surface marker expression, the T-cellare representative of three independent experiments. The expression
folds of pERK, pp38, and pJNK in LPS-stimulated DCs were compared
to that of cells without LPS treatment. The bar graphs are expressed as
the mean SD of the three independent experiments. (*p < 0.05, ***p
< 0.001) (B) The nuclear binding activity of NF-kB in the DCs was
assayed as described in the Materials and Methods section. The
activities of NF-kB in the phloretin-treated LPS-stimulated DCs were
compared to those in LPS-stimulated DCs with DMSO treatment (**p
< 0.01). (C) Inhibition of LPS-induced DC activation by speciﬁc inhib-
itors. The DCs were pretreated with PD98058 (10 mM), JNKI (10 mM),
SB203580 (10 mM), and BAY 11-7082 (10 mM) for 1 h and then stimu-
lated with LPS for 30 min. The whole or nuclear extracts were assayed
for the phosphorylation of ERK/JNK/p38 MAPK and NF-kB p65 by
western blotting, respectively (upper panels). For cytokine production,
the groups of DCs shown were stimulated by LPS for 18 h and the
supernatants were collected for the detection of IL-12 by ELISA. The
diﬀerences between the inhibitor-treated and the DMSO-treated LPS-
stimulated DCs are shown (***p < 0.001). All data are representative of
three independent experiments.
This journal is © The Royal Society of Chemistry 2014
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View Article Onlineproliferation, the percentage of CD4+/IFN-gamma+ T cells,
and the western blotting, were performed using one-way
ANOVA followed by Tukey's post hoc test. The values of
p < 0.05 were considered to be statistically signicant.
Results
Cytotoxicity of phloretin on mouse bone marrow derived DCs
To study the eﬀect of phloretin on DCs, we determined the cyto-
toxicity of phloretin on mouse bone marrow-derived DCs (BMDCs)
by CCK-8 assayrst. No signicant cell deathwas observed aer the
treatment of phloretin (<100 mM) alone or when combined with the
LPS (100 ng mL1) (Fig. 1A). Thus, the concentrations of phloretin
used in all of the experiments were always less than 50 mM.
Phloretin inhibited production of cytokines and chemokines
by LPS-stimulated BMDCs
When DCs are activated, they can produce cytokines and che-
mokines. Thus, we evaluated the eﬀects of phloretin on BMDCs
by detecting the amount of cytokines and chemokinesFig. 3 ROS production in LPS-stimulated DCs was impaired by phloretin. (
and then stimulatedwith 100 ngmL1 LPS for 6 h. The ROS generation withi
ﬂuorescence intensity (MFI). The data are expressed as themean SD of the
LPS-stimulated DCs by speciﬁc inhibitors. The DCs were pretreated with
stimulatedwith LPS for 6 h. ROS productionwasmeasured by ﬂowcytometr
expressed as themean SDof the triplicate; *p < 0.05, ***p < 0.001, n.s p >
for 18 h. The supernatants were collected for the determination of IL-12 pro
DMSO-treated LPS-activated DCs are shown (***p < 0.001, n.s p > 0.05).
This journal is © The Royal Society of Chemistry 2014produced. We did not see any activation of the BMDCs by
phloretin treatment alone (data not shown), suggesting that the
phloretin may not be a stimulant for DCs. We then treated the
BMDCs with various concentrations of phloretin (3.125, 6.25,
12.5, 25 or 50 mM) together with the LPS (100 ng mL1). The
amount of proinammatory cytokines (TNF-a, IL-6, IL-12), anti-
inammatory cytokine (IL-10), and chemokines (RANTES and
MIP-1b) was reduced in comparison to the treatment of the LPS
alone (Fig. 1B). In addition, this inhibitory eﬀect of phloretin on
TNF-a production, secreted by the LPS-stimulated BMDCs, was
signicant when adding phloretin both before and aer the LPS
stimulation (Fig. 1C). These results indicate that phloretin has a
suppressive eﬀect on the production of pro-inammatory cyto-
kines and chemokines by the LPS-stimulated DCs.
Phloretin blocked TNF-a production by BMDCs stimulated
with various TLR agonists
Phloretin also blocked the TNF-a production by BMDCs stim-
ulated with the LPS at a high concentration (1000 ng mL1)
(Fig. 1D). Furthermore, phloretin exerted a similar inhibitoryA) DCFDA-loaded DCs were pretreated with phloretin (25, 50 mM) for 1 h
n the cells was determined by ﬂow cytometry as represented by themean
triplicate; *p < 0.05, ***p < 0.001. (B) Inhibition of ROS production in the
NAC or CoPP-IX for 1 h before DMSO or phloretin treatment, and then
ywithDCFDA andwas shown by theMFI as described above. The data are
0.05. (C) TheDCswere treated as described in (B) and stimulatedwith LPS
duction by ELISA. The diﬀerences between the inhibitor-treated and the
All data are representative of three independent experiments.
Food Funct., 2014, 5, 997–1006 | 1001
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View Article Onlineeﬀect on BMDCs activated by various TLR agonists, such as PGN
(for TLR2), poly I:C (for TLR3), Imiquimod (for TLR7), and CpG
(for TLR9) (Fig. 1E). These data show that phloretin eﬃciently
blocks the TNF-a production by the activation of DCs via all of
the TLR signaling pathways.
Activation of MAPKs and NF-kB was disturbed by phloretin in
LPS-stimulated BMDCs
The activation of MAPKs and NF-kB in TLR signaling was crit-
ical for regulating the release of proinammatory cytokines and
chemokines in DCs. We subsequently investigated the involve-
ment of these signaling pathways in the suppressive eﬀect of
phloretin on DCs. MAPKs, including ERK 1/2, p38, and JNK,
were activated by BMDCs aer the LPS stimulation; however,
the phloretin decreased the phosphorylation of these MAPKs
but not the amounts of them (Fig. 2A). In addition, the nuclear
binding activity of NF-kB (p65) was also eﬀectively attenuated by
the phloretin in a dose-dependent manner (Fig. 2B). Next, we
used specic inhibitors to conrm that the reduction of the
MAPK and NF-kB activation might be the mechanism for the
suppressive eﬀect of phloretin on the DCs. The DCs were pre-
treated with SB203580 (for p38 MAPK), JNK inhibitor II (for
JNK), PD98059 (for ERK), and BAY 11-7082 (for NF-kB) for 1 h
and then stimulated with the LPS. These inhibitors signicantlyFig. 4 Phloretin attenuated LPS-induced DCmaturation. The DCs were p
100 ng mL1 LPS for 18 h. The control group was pretreated with 0.
determined by ﬂow cytometry. The MFI is indicated in each graph. The
were obtained from three independent experiments.
1002 | Food Funct., 2014, 5, 997–1006reduced the activation of MAPKs and NF-kB (Fig. 2C, upper
panels). The production of IL-12 decreased when assayed with
the DCs stimulated with the LPS in the presence of specic
inhibitors, including SB203580, JNK I and BAY 11-7082, or
inhibitors plus phloretin, but did not decrease with PD98059.
However, co-treatment with SB203580, JNK I or BAY 11-7082 did
not signicantly increase the suppressive eﬀect of phloretin
(Fig. 2C, lower panel), indicating that the inhibitory eﬀect of
phloretin on the LPS-stimulated DCs is overlapped with the
inhibitors used. Thus, we concluded that phloretin inhibits the
cytokine and chemokine production of the LPS-stimulated DCs
by disturbing the MAPKs and NF-kB signaling pathways.
Phloretin modulated ROS production in LPS-stimulated DCs
Reactive oxygen species (ROS) have been shown to participate in
the activation of DCs.26 To assess the eﬀect of phloretin on ROS
production, we analyzed the ROS levels in the DCs aer LPS
stimulation with or without phloretin pretreatment. As expec-
ted, phloretin reduced LPS-mediated ROS production in the
DCs (Fig. 3A). In order to conrm this suppressive mechanism,
LPS-stimulated DCs were pretreated with the antioxidant
N-acetyl-L-cysteine (NAC) or cobalt protoporphyrin-IX (CoPP). As
shown in Fig. 3B and C, NAC or CoPP (with or without phloretin)
signicantly reduced the ROS level and IL-12 production in theretreated with phloretin (25 and 50 mM) for 1 h and then stimulatedwith
1% DMSO. The expressions of MHC class II, CD40 and CD80, were
gray area represents the isotype-matched mAb control. Similar results
This journal is © The Royal Society of Chemistry 2014
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View Article OnlineLPS-stimulated DCs. Therefore, these results indicate that
phloretin suppresses cytokine production in LPS-stimulated
DCs via the inhibition of ROS production.Fig. 6 Suppression of the phenotypic maturation of the LPS-chal-
lenged splenic DCs by phloretin in vivo. The mice were injected i.p.Attenuation of LPS-induced DC maturation and the
subsequent induction of T cell activation by phloretin in vitro
Aer activation the DCs undergo a maturation process and then
initiate the adaptive immune responses. To investigate the
eﬀect of phloretin on DC maturation, we examined the expres-
sions of CD40, MHC class II and costimulatory molecule CD80
in BMDCs, which represent the key phenotypes of DC matura-
tion. The expression levels of CD40, MHC class II, and CD80 on
BMDCs stimulated by LPS were increased (mean uorescence
intensity (MFI) ¼ 4 to 16, 113 to 240 and 18 to 50, respectively),
but were dose-dependently reduced (MFI ¼ 16 to 11 and 7, 240
to 176 and 133, 50 to 30 and 24, respectively) by phloretin
(Fig. 4).
The primary function of mature DCs is to induce the acti-
vation and proliferation of naive T-cells. The treatment of
BMDCs with phloretin eﬀectively reduced their T cell priming
function in a mixed lymphocyte reaction (MLR) as the prolif-
eration of the cocultured naive T cells was suppressed (Fig. 5).
Collectively, we suggested that phloretin can attenuate LPS-
stimulated DC maturation and the subsequent induction of the
T cell activation by the activated DCs.with phloretin (10 mg kg1) for three times at two-day intervals and
then injected i.p. with the LPS (4 mg kg1). After 12 h, the splenocytes
were isolated and the CD11c+ DCs were assayed for the expression
levels of CD80 and I-Ab (MHC class II), as described in theMaterials and
Methods section. The MFI is indicated in each graph. The gray-ﬁlled
histograms represent the isotype-matched mAb control. The
expression levels (MFI) of CD80 and I-Ab are presented as the mean 
SD of the three samples. *p < 0.05; the data are representative of two
independent experiments (n ¼ 6 in each experiments).Suppression of LPS-induced DC maturation and T cell
activation by phloretin in vivo
The inhibitory eﬀect of phloretin on the DC activation and
maturation has been demonstrated in vitro. Therefore, we
further examined its inhibitory eﬀect in vivo. The B6 mice were
administered intraperitoneally with phloretin (10 mg kg1) for 3
times, as described in the Materials and Methods section, and
then were challenged with LPS (4 mg kg1). The splenic DCs
were harvested and analyzed for the expression of the MHC
class II and CD80 maturation markers. The expression levels of
MHC class II and CD80 were lower in the phloretin-treated DCsFig. 5 Phloretin impaired the T cell activation by LPS-stimulated DCs.
The DCs were pretreated with DMSO or phloretin for 1 h and then
stimulated with 100 ng mL1 LPS for 18 h. The CD4+ T cells isolated
from Balb/c mice were mixed with the DCs at the ratios of 1 : 2, 1 : 5
and 1 : 10 and incubated for 96 h. The proliferation of the cells was
determined by [3H]-thymidine incorporation assay. The data are
expressed as the mean  SD of the triplicate. **p < 0.01, ***p < 0.001;
similar results were obtained from three independent experiments.
This journal is © The Royal Society of Chemistry 2014than in DMSO-treated ones (Fig. 6). Next, we determined the
eﬀect of phloretin on DC-induced T cell activation by detecting
the IFN-g produced by the CD4 T cells. Consistently, the
percentage of IFN-g-producing CD4 T cells was reduced in the
phloretin-treated mice compared to DMSO control mice (from
10% to 3.5%) (Fig. 7). Thus, we concluded that phloretin can
suppress the phenotypic maturation of the DCs and impair the
T cell activation aer LPS treatment in vivo.Discussion
We identied the suppressive eﬀect of phloretin on DC activa-
tion and function in this study and provided both in vitro and
in vivo evidence. Phloretin has been shown to exert various
biological activities; however, here we reported for the rst time
that phloretin is an immunomodulator which can inhibit DC
function. This information may suggest that fruits containing
phloretin, especially apple, can promote health by reducing
harmful immunity.
Phloretin is a avonoid, a group of polyphenols with a large
spectrum of biological eﬀects.27,28 Many bioactivities ofFood Funct., 2014, 5, 997–1006 | 1003
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View Article Onlinephloretin have been reported, including antioxidant, anti-
inammation, and anti-cancer.15,29,30 Although several studies
have shown the suppressive eﬀect of phloretin on immune cells,
such as macrophages,15,31 osteoclasts,32 neutrophils,33 baso-
phils,34 and T cells,35,36 there is no report on DCs. It will be
interesting to explore the inhibitory eﬀect of phloretin on other
types of immune cell. These studies will provide cell-specic
information which is necessary for the development of powerful
immunosuppressants derived from phloretin.
Here we showed that phloretin disturbed multiple intracel-
lular signaling pathways in DCs, including MAPKs (ERK, JNK,
p38 MAPK) and NF-kB (Fig. 2), and these observations agree
with the eﬀects of phloretin on mouse skin37 and macro-
phages.15 NF-kB is critical for LPS-induced DC activation and
maturation, including cytokine and chemokine production,
and the up-regulation of costimulatory molecules.38 Further-
more, NF-kB subunits c-Rel and p50 control the expression of
the costimulatory molecule CD40 and IL-12 production by LPS-
stimulated DCs.39 Thus, the inhibition of NF-kB activation
might be an important mechanism for the suppressive eﬀect of
phloretin on DC activation.
We reported that phloretin can inhibit the LPS-induced
MAPK signaling pathways in the DCs. In contrast, recent studiesFig. 7 Phloretin impaired the IFN-g production by the CD4+ T cells in the
kg1) for three times at two-day intervals and then injected i.p. with LPS (4
PMA and ionomycin for 6 h, and then the production of IFN-g by the
Materials and Methods section. The percentages of the CD4+IFN-g+ cells
of four to six mice per group from two independent experiments (**p <
1004 | Food Funct., 2014, 5, 997–1006showed that the phloretin activatedMAPK pathways in HEI-OC1
auditory cells40 and enhanced p38 MAPK activation in PINK1–
KO astrocytes.41 There may be two possible explanations for the
diﬀerent eﬀects of phloretin on MAPK activities. One may be
due to diﬀerences in the species or the cell-type. Another
explanation could be that phloretin may regulate the upstream
of MAPK pathways but not MAPKs directly. Therefore, the
identication of the exact mechanisms responsible for these
diﬀerent eﬀects may be helpful for the application of phloretin
in the treatment of clinical diseases in the future.
In the specic inhibitor study, the IL-12 production was
decreased by LPS-stimulated DCs with SB203580 and JNKI, but
not PD98059 (Fig. 2C). It has been shown that LPS can activate
all three MAPKs in DCs; however, the inhibition of ERK1/2 by
PD98059 does not aﬀect the DCmaturation but rather regulates
DC survival. In contrast, the inhibition of p38 MAPK by
SB203580 profoundly reduces the phenotypic changes during
LPS-induced DC maturation.42,43 Thus, our data are consistent
with the diﬀerent regulation of MAPKs with regards to DC
activation and function. We suggest that p38 MAPK and JNK
pathways could be involved in the suppressive eﬀect of phlor-
etin on LPS-induced DCs maturation in this study. In addition
to the signaling pathways examined in this study, otherLPS-challengedmice. Themicewere injected i.p. with phloretin (10mg
mg kg1). After 12 h, the splenocytes were isolated and stimulated with
CD4+ T cells was analyzed using ﬂow cytometry as described in the
are indicated in the dot plots. The bar graphs represent the mean SD
0.01).
This journal is © The Royal Society of Chemistry 2014
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View Article Onlinemechanisms such as the blocking of protein kinase C,44 inhi-
bition of Akt activation,34 and the induction of PPARgamma
transcriptional activity45 have been reported. It will be impor-
tant to examine whether these pathways are also related to the
suppressive eﬀect of phloretin on DCs.
We also observed that phloretin, as well as the antioxidants
NAC and CoPP, attenuated ROS production in LPS-stimulated
DCs in this study (Fig. 3). ROS are known to inuence the
secretion of cytokine by the DCs and NAC inhibits the antigen
presentation of the DCs to the T cells.46 Another study showed
that CoPP reduces LPS-induced phenotypic maturation and
the secretion of proinammatory cytokines in human and rat
DCs, resulting in the inhibition of alloreactive T-cell prolifer-
ation.47 In addition, it has been reported that the LPS-induced
ROS generation and the related decline in glutathione (GSH)/
oxidized glutathione (GSSG) occur in human monocyte-
derived DCs and that the former is involved in cytokine
production, while the latter is involved in the up-regulation of
cell surface molecules and the allostimulatory capacity.48
Collectively, these results suggest that phloretin may suppress
ROS production through its antioxidant activity in LPS-stim-
ulated DCs.
We have proved the immunomodulatory eﬀect of phloretin
in vivo (Fig. 6 and 7); however, phloretin from fruits needs to be
absorbed in the gastrointestinal tract in order to exert its
functions. It has been shown that phloretin is found in the
urine of rats who have been fed apple juice49 and in the ileos-
tomy eﬄuent of humans aer apple juice consumption.50 Thus,
these reports suggest that direct ingestion of phloretin-con-
taining fruits may have immunomodulatory functions when
ingested directly. The strategies for promoting the function of
phloretin-containing fruits would be valuable to study.
In summary, our study illustrates that phloretin can
suppress DC activation and DC-induced T cell responses,
prompting us to speculate that phloretin could potentially be
used for the prevention and treatment of inammation, auto-
immunity, and transplantation. In addition, we suggest that
fruits containing phloretin can promote health by impairing
inammation-related diseases, especially in the elderly.
Although our results showed that phloretin aﬀects DC function
in vitro and in vivo, it remains to be revealed how this modu-
lation happens via oral administration. Analyzing more
compositions and immune functions in fruits will be important
issues in food research.Conﬂict of interest
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